嵌合抗原受体
医学
CD19
化疗
免疫学
急性淋巴细胞白血病
抗原
肿瘤科
癌症
内科学
儿科
T细胞
免疫系统
白血病
淋巴细胞白血病
作者
Persis Amrolia,Martin Pulé
出处
期刊:The Lancet
[Elsevier]
日期:2015-02-01
卷期号:385 (9967): 488-490
被引量:19
标识
DOI:10.1016/s0140-6736(14)61729-3
摘要
In The Lancet, Daniel Lee and colleagues 1 Lee DW Kochenderfer JN Stetler-Stevenson M et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; (published online Oct 13.)http://dx.doi.org/10.1016/S0140-6736(14)61403-3 Google Scholar report on a novel approach for the treatment of childhood acute lymphoblastic leukaemia, with important implications for other cancers. B-lineage acute lymphoblastic leukaemia is the commonest childhood cancer, with some 400 new cases a year in the UK. Despite major advances, 15% of children do not respond to currently available treatments, including chemotherapy and stem cell transplantation, and untreatable relapse remains a leading cause of childhood cancer deaths. In adult patients, relapse is more frequent and often unsalvageable. Since such patients have often had the maximum tolerable dose of chemotherapy and radiotherapy, there is a pressing need for novel treatment strategies to treat relapse in acute lymphoblastic leukaemia. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialCD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI